<b>Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?</b>
media
posted on 2025-09-23, 07:13 authored by Adis journals on behalf of, Eric L. Simpson, Jonathan I. Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M. Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner<p dir="ltr"><b>Article full text</b> The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above Graphical Abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).</p>
